GlassScriptPhysician profile
John Onsek Lai
NPI 1457398406
$34,536.46
in general payments reported to CMS, 2019-2025
62 companies · $4,581 in 2025
The $4,581 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,781 · 2020: $4,128 · 2021: $5,516 · 2022: $4,970 · 2023: $5,108 · 2024: $5,454 · 2025: $4,581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $1.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,140.43 |
| Education | $1.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $4,513.94 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $4,311.21 | 2019-2025 | Jardiance, Spiriva Respimat, Ofev |
| Astrazeneca Pharmaceuticals LP | $4,178.64 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $2,321.83 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $1,870.33 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $1,280.94 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,137.85 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Cmp Pharma, INC. | $1,105.87 | 2021-2025 | Atorvaliq, Norliqva, Tadliq |
| Amgen INC. | $1,103.64 | 2019-2025 | Repatha, Otezla, Repatha |
| E.R. Squibb & Sons, L.L.C. | $921.75 | 2019-2025 | Eliquis, Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $912.82 | 2019-2024 | Lifevest |
| Pfizer INC. | $878.77 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $859.06 | 2019-2025 | |
| Gilead Sciences, INC. | $793.09 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $732.99 | 2019-2025 | Verquvo, Belsomra, Januvia |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.